<DOC>
	<DOCNO>NCT00865605</DOCNO>
	<brief_summary>The purpose study compare vasoconstriction response profile bioequivalence one innovator lot UltravateÂ® 0.05 % ointment one test/generic lot Halobetasol propionate 0.05 % ointment ( Alpharma USPD , Inc. ) .</brief_summary>
	<brief_title>Pivotal Bioequivalence Study Topically Delivered Halobetasol Propionate Ointment Normal Skin Healthy Adult Subjects</brief_title>
	<detailed_description>Study Type : Interventional Study Design : A single blind , single-exposure study healthy adult male female subject . Official Title : A Single-blind , Single Exposure Study , Evaluate Vasoconstriction Activity Topically Delivered Halobetasol Propionate Ointment Normal Skin Healthy Adult Subjects : Pivotal Bioequivalence Study Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Vasoconstrictor Response</detailed_description>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Halobetasol</mesh_term>
	<criteria>Subject understands study , willing participate , give write informed consent . Subject demonstrate adequate vasoconstriction screen topical corticosteroid Halobetasol propionate 0.05 % ointment within 30 day dose . Subject nonsmoking ( minimum 14 day ) , male female , age 18 65 year , inclusive . Subject within 20 % ideal body weight defined 1999 Metropolitan Life Insurance Company Height Weight Tables . Subject judge Investigator healthy basis prestudy medical history . Subjects childbearing potential agree use acceptable method birth control study participation ( e.g . abstinence , prescribed birth control method , double barrier method , Le . condom plus foam , condom plus diaphragm ) . Subject willing refrain excessive consumption sodium food beverage 48hrs duration study . Subject willing shower use soap/cleansers duration study . Subject willing follow study restriction . Subject past current medical condition might significantly affect pharmacodynamic response topical corticosteroid . Subject diabetes mellitus , clinically significant hypertension circulatory disease . Subject take medication regular basis could modulate blood flow ( constrictor dilator ) , exception prescribe birth control method hormone replacement therapy . Examples drug include nitroglycerin , anti hypertensive , antihistamine , NSAIDs , aspirin , phenylpropanolamine , phentolamine medication deem inappropriate Investigator . Subject planning use exclusionary overthecounter ( OTC ) medication within 48 hour prior throughout study could modulate vascular blood flow . Subject intend start , stop change dose prescription OTC medication within 48 hour prior throughout study . Acetaminophen may administer , need . Subject used prescription OTC topical medication ventral forearm within 1 month prior study conduct . Subject history sensitivity/allergy ingredient find test formulation history adverse reaction topical systemic corticosteroid . Subject significant history allergy soap , lotion , emollient , ointment , cream , cosmetic , adhesive , latex . Subject history significant skin condition disorder , example , psoriasis , atopic dermatitis , etc . Subject history significant dermatologic cancer , example , melanoma squamous cell carcinoma . Basal cell carcinomas superficial involve investigative site acceptable . Subject obvious difference skin color arm presence skin condition , scar tissue , tattoo coloration would interfere placement test site , assessment , reaction drug could compromise safety subject . Subject use topical medication ventral forearm within 1 month prior dose . Subject use tobacco product within 14 day study conduct . Subject clinically significant history drug abuse alcoholism . Subject donate received blood within 30 day prior dose . Subject 's caffeine intake great 500 mg per day ( 1 cup coffee contain approximately 85 mg caffeine ) . Subject unwilling abstain alcohol caffeine 48 hour prior throughout study . ( Females ) : Subject pregnant lactating . Subject participate another investigational drug , medical device , biologics study within 30 day prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>Vasoconstriction</keyword>
	<keyword>Halobetasol</keyword>
	<keyword>Healthy subject</keyword>
</DOC>